RESUMO
BACKGROUND: Half of all postmenopausal women report symptoms of vulvar, vaginal, or urinary discomfort with substantial impact on sexual function and quality of life; underlying mechanisms leading to symptoms are poorly understood. OBJECTIVE: To examine the possibility that the vaginal microbiota and/or mucosal immune response contributes to the severity of bothersome vaginal symptoms, we conducted a substudy of samples from a randomized trial of vaginal treatment for genitourinary syndrome of menopause to compare these features between women whose symptoms improved and women whose symptoms did not improve. STUDY DESIGN: This is a secondary analysis of samples collected in a 12-week randomized trial of treatment with vaginal estradiol or moisturizer vs placebo for moderate-severe postmenopausal symptoms of vaginal discomfort. We randomly selected 20 women in each arm with ≥2-point decrease in most bothersome symptom severity (responders) and 20 matched controls with ≤1-point decrease (nonresponders). At 0, 4, and 12 weeks, we characterized vaginal microbiota (16S ribosomal RNA gene sequencing), vaginal fluid metabolites (broad-based metabolomic profiling), vaginal fluid-soluble immune markers (Meso Scale Discovery), pH, and vaginal maturation index. We compared responders with nonresponders at baseline and across all visits using linear mixed models to evaluate associations with microbiota, metabolites, and immune markers, incorporating visit and participant-specific random effects while controlling for treatment arm. RESULTS: Here, the mean age of women was 61 years (n=120), and most women (92%) were White. At enrollment, no significant differences were observed between responders and nonresponders in age, most bothersome symptom type or severity, microbiota composition or diversity, Lactobacillus dominance, metabolome, or immune markers. There was a significant decrease in diversity of the vaginal microbiota in both responders and nonresponders (P<.001) over 12 weeks. Although this change did not differ by responder status, diversity was associated with treatment arm: more women in the estradiol arm (63%) had Lactobacillus-dominant, lower diversity bacterial communities than women in the moisturizer (35%) or dual placebo (23%) arms (P=.001) at 12 weeks. The metabolome, vaginal maturation index, and measured immune markers were not associated with responder status over the 12 weeks but varied by treatment arm. CONCLUSION: Postmenopausal vaginal symptom severity was not significantly associated with vaginal microbiota or mucosal inflammatory markers in this small study. Women receiving vaginal estradiol experienced greater abundance of lactobacilli and lower vaginal pH at end of treatment.
Assuntos
Citocinas/metabolismo , Estradiol/administração & dosagem , Estrogênios/administração & dosagem , Doenças Urogenitais Femininas/tratamento farmacológico , Inflamação/metabolismo , Microbiota/genética , Pós-Menopausa , Vagina/microbiologia , Administração Intravaginal , Idoso , Citocinas/imunologia , Feminino , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/metabolismo , Doenças Urogenitais Femininas/microbiologia , Humanos , Concentração de Íons de Hidrogênio , Inflamação/imunologia , Lactobacillus , Metaboloma , Metabolômica , Pessoa de Meia-Idade , RNA Ribossômico 16S/genética , Índice de Gravidade de Doença , Resultado do Tratamento , Vagina/imunologia , Vagina/metabolismo , Cremes, Espumas e Géis VaginaisRESUMO
Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory disease characterized by focal or diffuse organ infiltration of IgG4-bearing plasma cells. The diagnosis of IgG4-RD is based on a combination of clinical, serologic, radiologic, and histopathologic findings. IgG4-RD has been reported to affect almost all organ systems. The kidney is the most frequently involved of the genitourinary organs. The most common renal manifestation of IgG4-RD is IgG4-RD tubulointerstitial nephritis, followed by membranous glomerulonephropathy and, less frequently, obstructive nephropathy involving the renal pelvis, ureter, or retroperitoneum. Renal parenchymal lesions may appear as multiple nodular lesions, diffuse patchy infiltrative lesions, or a single nodular lesion. Multiple small nodular cortical lesions are the most common imaging findings of IgG4-RD involving the kidney. Renal pelvic, sinus, or perinephric lesions can also occur. IgG4-RD involvement of other genitourinary organs including the ureter, bladder, urethra, and male and female reproductive organs is rare compared with kidney involvement but may show variable imaging findings such as a localized mass within or surrounding the involved organ or diffuse enlargement of the involved organ. Imaging findings of IgG4-RD involving the genitourinary system are nonspecific but should be differentiated from inflammatory and neoplastic lesions that mimic IgG4-RD. The online slide presentation from the RSNA Annual Meeting is available for this article. ©RSNA, 2020.
Assuntos
Doenças Urogenitais Femininas/diagnóstico por imagem , Doenças Urogenitais Femininas/imunologia , Doença Relacionada a Imunoglobulina G4/diagnóstico por imagem , Doenças Urogenitais Masculinas/diagnóstico por imagem , Doenças Urogenitais Masculinas/imunologia , Diagnóstico Diferencial , Feminino , Humanos , MasculinoRESUMO
PURPOSE: Imaging features of immune-mediated genitourinary diseases often overlap, and the same disease may manifest in different ways, so understanding imaging findings in the context of the patient's entire clinical picture is important in providing the correct diagnosis. METHODS: In this article, diseases mediated by the immune system which affect the genitourinary system are reviewed. Examples of immune-mediated genitourinary disease including IgG4-related disease, post-transplant lymphoproliferative disorder, immunodeficiency-associated lymphoproliferative disorder due to immunosuppressive and immunomodulatory medications, lymphoma, leukemia, myeloma, amyloidosis, and histiocytosis. RESULTS: Clinical and imaging features will be presented which may help narrow the differential diagnosis for each disease. CONCLUSION: Recognition of immune-related genitourinary disease is important for appropriate medical management as they may mimic other diseases both by imaging and clinical presentation.
Assuntos
Amiloidose/diagnóstico por imagem , Doenças Urogenitais Femininas/diagnóstico por imagem , Histiocitose/diagnóstico por imagem , Doença Relacionada a Imunoglobulina G4/diagnóstico por imagem , Leucemia/diagnóstico por imagem , Linfoma/diagnóstico por imagem , Transtornos Linfoproliferativos/diagnóstico por imagem , Doenças Urogenitais Masculinas/diagnóstico por imagem , Mieloma Múltiplo/diagnóstico por imagem , Amiloidose/imunologia , Diagnóstico Diferencial , Feminino , Doenças Urogenitais Femininas/imunologia , Histiocitose/imunologia , Humanos , Doença Relacionada a Imunoglobulina G4/imunologia , Leucemia/imunologia , Linfoma/imunologia , Transtornos Linfoproliferativos/imunologia , Masculino , Doenças Urogenitais Masculinas/imunologia , Mieloma Múltiplo/imunologiaRESUMO
BACKGROUND: The tryptophan-depleting enzyme indoleamine-2,3-dioxygenase (IDO) is critical for the regulation of immunotolerance and plays an important role in immune-associated skin diseases. OBJECTIVES: To analyse the level of IDO in condyloma acuminata (CA) and its role in this condition. METHODS: IDO expression was assessed in the skin and peripheral blood of healthy controls and patients with CA. To assess the role of skin IDO in immunity, the ability of isolated epidermal cells to metabolize tryptophan and the influence on polyclonal T-cell mitogen (PHA)-stimulated T-cell proliferation were explored. RESULTS: IDO median fluorescence intensities in peripheral blood mononuclear cells from patients with CA were similar to those from healthy controls. Immunohistochemistry showed that IDO+ cells were rare in normal skin and the control skin of patients with CA, but were greatly accumulated in wart tissue. Most fluorescence signals of IDO+ cells did not overlap with those of CD1a+ Langerhans cells. Human papillomavirus (HPV) DNA probe in situ hybridization showed a large number of IDO+ cells in the HPV- site. Keratinocytes in the skin of healthy controls and the circumcised skin of patients with CA could minimally transform tryptophan into kynurenine, but IDO-competent epidermal cells from warts could transform tryptophan. In addition, these IDO-competent epidermal cells could inhibit PHA-stimulated T-cell proliferation. The addition of an IDO inhibitor, 1-methyl-d-tryptophan, restored the inhibited T-cell proliferation. CONCLUSIONS: Abnormally localized high IDO expression might be involved in the formation of a local immunotolerant microenvironment.
Assuntos
Doenças do Ânus/enzimologia , Condiloma Acuminado/enzimologia , Doenças Urogenitais Femininas/enzimologia , Indolamina-Pirrol 2,3,-Dioxigenase/metabolismo , Doenças Urogenitais Masculinas/enzimologia , Adulto , Doenças do Ânus/imunologia , Estudos de Casos e Controles , Proliferação de Células/fisiologia , Células Cultivadas , Condiloma Acuminado/imunologia , Feminino , Doenças Urogenitais Femininas/imunologia , Humanos , Tolerância Imunológica/fisiologia , Indolamina-Pirrol 2,3,-Dioxigenase/imunologia , Leucócitos Mononucleares/enzimologia , Masculino , Períneo , Linfócitos T/virologia , Triptofano/metabolismoAssuntos
Humanos , Masculino , Feminino , Adulto , Arginase/metabolismo , Artrite Reativa/microbiologia , Artrite Reativa/virologia , Leucócitos Mononucleares/microbiologia , Leucócitos Mononucleares/virologia , Óxido Nítrico Sintase Tipo III/metabolismo , Óxido Nítrico/metabolismo , Artrite Reativa/complicações , Artrite Reativa/imunologia , Infecções Bacterianas/complicações , Infecções Bacterianas/imunologia , Infecções Bacterianas/microbiologia , Estudos de Casos e Controles , Chlamydia trachomatis/classificação , Chlamydia trachomatis/isolamento & purificação , Doenças Urogenitais Femininas/complicações , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/microbiologia , Doenças Urogenitais Femininas/virologia , Gastroenteropatias/complicações , Gastroenteropatias/imunologia , Gastroenteropatias/microbiologia , Gastroenteropatias/virologia , Hepacivirus/classificação , Hepacivirus/isolamento & purificação , Vírus da Hepatite B/classificação , Vírus da Hepatite B/isolamento & purificação , Hepatite/complicações , Hepatite/imunologia , Hepatite/virologia , Leucócitos Mononucleares/imunologia , Doenças Urogenitais Masculinas/complicações , Doenças Urogenitais Masculinas/imunologia , Doenças Urogenitais Masculinas/microbiologia , Doenças Urogenitais Masculinas/virologia , Doenças Nasofaríngeas/complicações , Doenças Nasofaríngeas/imunologia , Doenças Nasofaríngeas/microbiologia , Doenças Nasofaríngeas/virologia , Cultura Primária de Células , Streptococcus pyogenes/classificação , Streptococcus pyogenes/isolamento & purificaçãoRESUMO
Hosts are expected to incur several physiological costs in defending against parasites. These include constitutive energetic (or other resource) costs of a defence system, facultative resource costs of deploying defences when parasites strike, and immunopathological costs of collateral damage. Here, we investigate the evolution of host recovery rates, varying the source and magnitude of immune costs. In line with previous work, we find that hosts paying facultative resource costs evolve faster recovery rates than hosts paying constitutive costs. However, recovery rate is more sensitive to changes in facultative costs, potentially explaining why constitutive costs are hard to detect empirically. Moreover, we find that immunopathology costs which increase with recovery rate can erode the benefits of defence, promoting chronicity of infection. Immunopathology can also lead to hosts evolving low recovery rate in response to virulent parasites. Furthermore, when immunopathology reduces fecundity as recovery rate increases (e.g. as for T-cell responses to urogenital chlamydiosis), then recovery and reproductive rates do not covary as predicted in eco-immunology. These results suggest that immunopathological and resource costs have qualitatively different effects on host evolution and that embracing the complexity of immune costs may be essential for explaining variability in immune defence in nature.
Assuntos
Evolução Biológica , Interações Hospedeiro-Patógeno , Chlamydiaceae/fisiologia , Infecções por Chlamydiaceae/imunologia , Infecções por Chlamydiaceae/microbiologia , Feminino , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/microbiologia , Humanos , Modelos Biológicos , Reprodução , Linfócitos T/imunologiaRESUMO
The own observations results of urogenital, gastrointestinal and nasopharyngeal infectious factors that cause the development of reactive arthritis (PeA) are being presented. The greatest contribution to the development of this disease make Chlamidia trachomatis (36%), Streptococcus haemolyticus (pyogenes) (19%) and hepatitis viruses B and C (10%). As a result of the research a number of kinetic parameters of arginase and NO-synthase reactions in peripheral blood lymphocytes of patients with reactive arthritis was identified. The authentic increase of arginase activity in 3.3 times and eNO-synthase activity decrease by 1,9 times in peripheral blood lymphocytes of patients with PeA, compared to practically healthy donors were determined. Increased activity of arginase and iNO-synthase of lymphocytes indicates changes in immune cells functional activity, which may be due to impaired metabolic and regulatory processes in these cells caused by a bacterial or viral infection.
Assuntos
Arginase/metabolismo , Artrite Reativa/microbiologia , Artrite Reativa/virologia , Leucócitos Mononucleares/microbiologia , Leucócitos Mononucleares/virologia , Óxido Nítrico Sintase Tipo III/metabolismo , Óxido Nítrico/metabolismo , Adulto , Artrite Reativa/complicações , Artrite Reativa/imunologia , Infecções Bacterianas/complicações , Infecções Bacterianas/imunologia , Infecções Bacterianas/microbiologia , Estudos de Casos e Controles , Chlamydia trachomatis/classificação , Chlamydia trachomatis/isolamento & purificação , Feminino , Doenças Urogenitais Femininas/complicações , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/microbiologia , Doenças Urogenitais Femininas/virologia , Gastroenteropatias/complicações , Gastroenteropatias/imunologia , Gastroenteropatias/microbiologia , Gastroenteropatias/virologia , Hepacivirus/classificação , Hepacivirus/isolamento & purificação , Hepatite/complicações , Hepatite/imunologia , Hepatite/virologia , Vírus da Hepatite B/classificação , Vírus da Hepatite B/isolamento & purificação , Humanos , Leucócitos Mononucleares/imunologia , Masculino , Doenças Urogenitais Masculinas/complicações , Doenças Urogenitais Masculinas/imunologia , Doenças Urogenitais Masculinas/microbiologia , Doenças Urogenitais Masculinas/virologia , Doenças Nasofaríngeas/complicações , Doenças Nasofaríngeas/imunologia , Doenças Nasofaríngeas/microbiologia , Doenças Nasofaríngeas/virologia , Cultura Primária de Células , Streptococcus pyogenes/classificação , Streptococcus pyogenes/isolamento & purificaçãoRESUMO
Animal models of human disease are important tools in many areas of biomedicine; for example, in infectious disease research and in the development of novel drugs and medical devices. Most studies involving animals use rodents, in particular congenic mice, due to the availability of a wide number of strains and the ease with which they can be genetically manipulated. The use of mouse models has led to major advances in many fields of research, in particular in immunology but despite these advances, no animal model can exactly reproduce all the features of human disease. It is increasingly becoming recognised that in many circumstances mice do not provide the best model and that alternative species may be more appropriate. Here, we describe the relative merits of sheep as biomedical models for human physiology and disease in comparison to mice, with a particular focus on reproductive and respiratory pathogens.
Assuntos
Modelos Animais de Doenças , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Masculinas/imunologia , Doenças Respiratórias/imunologia , Ovinos/imunologia , Animais , Pesquisa Biomédica , Feminino , Doenças Urogenitais Femininas/patologia , Humanos , Masculino , Doenças Urogenitais Masculinas/patologia , Camundongos , Doenças Respiratórias/patologiaRESUMO
IgG4-related autoimmune pancreatitis is frequently accompanied by relevant lesions in the genitourinary tract and retroperitoneal organs, which cause various clinical problems, ranging from non-specific back pain or bladder outlet obstruction to renal failure. The diagnosis of IgG4-related retroperitoneal fibrosis requires a multidisciplinary approach, including serological tests, histological examination, imaging analysis, and susceptibility to steroid therapy. Radiological examinations are helpful to diagnose this condition, but surgical resection is occasionally unavoidable to exclude malignancy, particularly for patients with isolated retroperitoneal involvement. Steroid therapy is the treatment of choice for this condition, the same as for other manifestations of IgG4-related disease. For patients with severe ureteral obstruction, additional ureteral stenting needs to be considered prior to steroid therapy to preserve the renal function. Some papers have suggested that IgG4-related disease can affect male reproductive organs including the prostate and testis. IgG4-related prostatitis usually causes lower urinary tract symptoms, such as dysuria and pollakisuria. Patients sometimes state that corticosteroids given for IgG4-related disease at other sites relieve their lower urinary tract symptoms, which leads us to suspect prostatic involvement in this condition. Because of the limited number of publications available, further studies are warranted to better characterize IgG4-related disease in male reproductive organs.
Assuntos
Doenças Autoimunes/imunologia , Doenças Urogenitais Femininas/imunologia , Imunoglobulina G/sangue , Doenças Urogenitais Masculinas/imunologia , Pancreatite/imunologia , Fibrose Retroperitoneal/imunologia , Corticosteroides/uso terapêutico , Animais , Doenças Autoimunes/sangue , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/tratamento farmacológico , Biomarcadores/sangue , Diagnóstico por Imagem/métodos , Doenças Urogenitais Femininas/sangue , Doenças Urogenitais Femininas/diagnóstico , Doenças Urogenitais Femininas/terapia , Humanos , Masculino , Doenças Urogenitais Masculinas/sangue , Doenças Urogenitais Masculinas/diagnóstico , Doenças Urogenitais Masculinas/terapia , Pancreatite/sangue , Pancreatite/diagnóstico , Pancreatite/tratamento farmacológico , Valor Preditivo dos Testes , Fibrose Retroperitoneal/sangue , Fibrose Retroperitoneal/diagnóstico , Fibrose Retroperitoneal/terapia , Fatores de Risco , Fatores Sexuais , Stents , Resultado do TratamentoRESUMO
Innate and adaptive immunity play a significant role in urogenital infections. Innate immunity is provided by the epithelial cells and mucus lining along with acidic pH, which forms a strong physical barrier against the pathogens in female reproductive tract. Cells of innate immune system, antimicrobial peptides, cytokines, chemokines and adaptive immunity in the reproductive tract are evolved during infection, and a pro-inflammatory response is generated to fight against the invading pathogen Trichomonas vaginalis, a primary urogenital protozoa, the etiological agent of human trichomoniasis, a curable sexually transmitted infection. The involvement of the urogenital tract by other protozoal infections such as P. falciparum, Trypanosoma, Leishmania, Toxoplasma, Entamoeba histolytica and Acanthamoeba infection is rarely reported. Trichomonas induce pro-inflammatory and immunosuppressive responses in infected subjects. Multifactorial pathogenic mechanisms including parasite adherence, cysteine proteases, lipophosphoglycan, free radical, cytokine generation and Toll-like receptors appear to interplay with the induction of local and systemic immune responses that ultimately determine the outcome of the infection. However, the involvement of urogenital pathogen-specific immune mechanisms and effect of normal local resident flora on the outcome (symptomatic vs. asymptomatic) of infection are poorly understood. Moreover, immune interactions in trichomoniasis subjects co-infected with bacterial and viral pathogens need to be elucidated.
Assuntos
Imunidade Adaptativa , Doenças Urogenitais Femininas/imunologia , Imunidade Inata , Doenças Urogenitais Masculinas/imunologia , Infecções por Protozoários/imunologia , Feminino , Doenças Urogenitais Femininas/parasitologia , Humanos , Masculino , Doenças Urogenitais Masculinas/parasitologiaRESUMO
OBJECTIVE: To test the adjuvant use of the combination of N-palmitoylethanolamine and transpolydatin in the medical treatment of endometriotic pain. STUDY DESIGN: We enrolled 47 patients admitted to the Outpatient Endometriosis Care Unit of Ferrara University from January 2011 to December 2011. They were divided into two groups according to the endometriosis site (group A: recto-vaginal septum; group B: ovary). One tablet, containing 400 mg of micronized N-palmitoylethanolamine plus 40 mg transpolydatin, was administered twice daily on a full stomach for 90 days. Each patient was requested to grade the severity of dysmenorrhea, chronic pelvic pain, dyspareunia and dyschezia using a 0-10 cm visual analogic scale prior to beginning treatment (T0), after 30 days (T1), 60 days (T2) and 90 days (T3). The continuous and categorical variables were compared, respectively, using Student's t-test and the chi-square test. Analysis of variance for repeated measures was used to verify the reduction of endometriotic pain. RESULTS: The intensity of endometriotic pain decreased significantly for both groups (p<0.0001). The efficacy of drug treatment was significant after 30 days. Pain intensity decreased equally in the two groups except for dysmenorrhea, which was reduced more rapidly in group B. CONCLUSIONS: The combination of N-palmitoylethanolamine and transpolydatin reduced pain related to endometriosis irrespective of lesion site. It had a marked effect on chronic pelvic pain determined by deep endometriosis and on dysmenorrhea correlated to ovarian endometriosis.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Endocanabinoides/uso terapêutico , Endometriose/tratamento farmacológico , Etanolaminas/uso terapêutico , Doenças Urogenitais Femininas/tratamento farmacológico , Glucosídeos/uso terapêutico , Ácidos Palmíticos/uso terapêutico , Dor Pélvica/prevenção & controle , Estilbenos/uso terapêutico , Adulto , Amidas , Anti-Inflamatórios não Esteroides/química , Dor Crônica/etiologia , Dor Crônica/prevenção & controle , Anticoncepcionais Orais Combinados/uso terapêutico , Combinação de Medicamentos , Quimioterapia Combinada , Dismenorreia/etiologia , Dismenorreia/prevenção & controle , Endometriose/imunologia , Endometriose/fisiopatologia , Fáscia/efeitos dos fármacos , Fáscia/imunologia , Feminino , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/fisiopatologia , Glucosídeos/química , Humanos , Pessoa de Meia-Idade , Doenças Ovarianas/tratamento farmacológico , Doenças Ovarianas/imunologia , Doenças Ovarianas/fisiopatologia , Medição da Dor , Dor Pélvica/etiologia , Estudos Prospectivos , Estereoisomerismo , Estilbenos/química , Adulto JovemRESUMO
PROBLEM: Untreated celiac disease (CD) is often associated with early miscarriages, infertility, and alterations in menstrual cycle. Tissue transglutaminase (tTG) antibodies could be involved by interfering with tTG transamidating activity and/or biological functions mediated by its interaction with fibronectin (FN). METHOD OF STUDY: The correlation between the presence of extra-digestive disorders and the reactivity of sera against tTG-FN and its effects on tTG transamidating activity was analyzed in a group or 50 women with recently diagnosed CD. RESULTS: Heterogeneous behavior was observed among serum samples derived from patients with different complaints, suggesting that differences in fine specificity patterns could condition clinical outcome. Sera from women with gynecological and/or obstetric problems induced significant inhibition of in vitro enzymatic activity in comparison with those without these kinds of disorders. CONCLUSIONS: The significant correlation observed between serum effects and clinical profile suggests a putative involvement of tTG-specific antibodies in gynecological and/or obstetric disorders during active CD.
Assuntos
Autoanticorpos/sangue , Autoanticorpos/imunologia , Doença Celíaca/complicações , Doenças Urogenitais Femininas/fisiopatologia , Complicações na Gravidez/fisiopatologia , Transglutaminases/metabolismo , Adolescente , Adulto , Autoimunidade , Doença Celíaca/sangue , Doença Celíaca/diagnóstico , Feminino , Doenças Urogenitais Femininas/imunologia , Fibronectinas/metabolismo , Humanos , Pessoa de Meia-Idade , Gravidez , Complicações na Gravidez/imunologia , Transglutaminases/imunologia , Adulto JovemRESUMO
We have previously shown that individuals infected with Chlamydia trachomatis can develop a robust antibody response to a Chlamydia type III secretion effector protein called Tarp and that immunization with Tarp induces protection against challenge infection in mice. The current study aimed to map the immunodominant regions of the Tarp protein by expressing 11 fragments of Tarp as glutathione S-transferase (GST) fusion proteins and detecting the reactivity of these fusion proteins with antisera from patients infected with C. trachomatis in the urogenital tract or in the ocular tissue and from rabbits immunized with C. trachomatis organisms. A major immunodominant region was strongly recognized by all antibodies. This region covers amino acids 152 to 302, consisting of three repeats (amino acids 152 to 201, 202 to 251, and 252 to 302). Each of the repeats contains multiple tyrosine residues that are phosphorylated by host cell kinases when Tarp is injected into host cells. Several other minor immunodominant regions were also identified, including those comprising amino acids 1 to 156, 310 to 431, and 582 to 682 (recognized by antisera from both humans and rabbits), that comprising amino acids 425 to 581 (recognized only by human antisera), and that comprising amino acids 683 to 847 (preferentially recognized by rabbit antisera). This immunodominance was also confirmed by the observations that six out of the nine monoclonal antibodies (MAbs) bound to the major immunodominant region and that the other three each bound to one of the minor fragments, comprising amino acids 1 to 119, 120 to 151, and 310 to 431. The antigenicity analyses have provided important information for further understanding the structure and function of Tarp.
Assuntos
Proteínas de Bactérias/imunologia , Chlamydia trachomatis/imunologia , Mapeamento de Epitopos , Epitopos Imunodominantes , Fatores de Virulência/imunologia , Animais , Anticorpos Antibacterianos/sangue , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/isolamento & purificação , Infecções por Chlamydia/imunologia , Feminino , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/microbiologia , Humanos , Camundongos , Camundongos Endogâmicos BALB C , CoelhosAssuntos
Papel do Médico , Complicações Infecciosas na Gravidez/etiologia , Efeitos Tardios da Exposição Pré-Natal/etiologia , Psiquiatria , Esquizofrenia/etiologia , Citocinas/sangue , Feminino , Doenças Urogenitais Femininas/complicações , Doenças Urogenitais Femininas/genética , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/prevenção & controle , Feto/imunologia , Predisposição Genética para Doença/genética , Humanos , Recém-Nascido , Vírus da Influenza A Subtipo H1N1/imunologia , Influenza Humana/complicações , Influenza Humana/genética , Influenza Humana/imunologia , Influenza Humana/prevenção & controle , Gravidez , Complicações Infecciosas na Gravidez/genética , Complicações Infecciosas na Gravidez/imunologia , Complicações Infecciosas na Gravidez/prevenção & controle , Efeitos Tardios da Exposição Pré-Natal/imunologia , Efeitos Tardios da Exposição Pré-Natal/prevenção & controle , Fatores de Risco , Esquizofrenia/genética , Esquizofrenia/imunologia , Esquizofrenia/prevenção & controle , Toxoplasmose Congênita/complicações , Toxoplasmose Congênita/genética , Toxoplasmose Congênita/imunologia , Toxoplasmose Congênita/prevenção & controle , Adulto JovemAssuntos
Infecções por Clostridium/imunologia , Clostridium sordellii/efeitos dos fármacos , Clostridium sordellii/imunologia , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/microbiologia , Imunidade Inata/efeitos dos fármacos , Misoprostol/efeitos adversos , Abortivos não Esteroides/efeitos adversos , Animais , Infecções por Clostridium/microbiologia , Feminino , Humanos , RatosRESUMO
There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring body's normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers new opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response.
Assuntos
Infecções Bacterianas/terapia , Gastroenteropatias/terapia , Probióticos/uso terapêutico , Infecções Bacterianas/imunologia , Feminino , Doenças Urogenitais Femininas/imunologia , Doenças Urogenitais Femininas/microbiologia , Doenças Urogenitais Femininas/terapia , Gastroenteropatias/imunologia , Gastroenteropatias/microbiologia , Infecções por Helicobacter/imunologia , Infecções por Helicobacter/terapia , Humanos , Imunidade Inata , Imunidade nas Mucosas , Mucosa Intestinal/imunologia , Mucosa Intestinal/microbiologia , Doenças da Boca/imunologia , Doenças da Boca/microbiologia , Doenças da Boca/terapia , Mucosa Bucal/imunologia , Mucosa Bucal/microbiologia , Infecções Respiratórias/imunologia , Infecções Respiratórias/terapia , Infecções Urinárias/imunologia , Infecções Urinárias/microbiologia , Infecções Urinárias/terapiaRESUMO
Levels of expression of hBD-1 gene (beta-defensin 1) and Toll-like receptors (TLR1, TLR2, TLR6) in cells of cervical mucosa in healthy nonpregnant and healthy pregnant women as well as in pregnant women with urogenital infection was measured by developed RT-PCR systems. During normal pregnancy compared with nonpregnant women, increase of TLRs genes expression which was correlated with increase of hBD-1 gene expression was observed. During urogenital infection in pregnant women compared with healthy pregnant, 10- fold and 50-fold increase of TLR1 and TLR2 genes expression respectively was associated with 2.5-fold decrease of hBD-1 gene expression in cervical mucosa. In group of women with untrauterine infection more marked increase of TLRs genes expression was observed. Thus significant changes (TLRs, antimicrobial peptides, cytokines etc.) in cells of cervical mucosa can be used as prognostic criteria for development of intrauterine infection.